Table 2: Clinical antiviral activity of the most important approved protease inhibitors (mean or median maximum HCV viral load decline after 3–14 days’ monotherapy [log10 IU/ml]
adapted from Sarrazin 2016 [19]
Table 2: Clinical antiviral activity of the most important approved protease inhibitors (mean or median maximum HCV viral load decline after 3–14 days’ monotherapy [log10 IU/ml]
adapted from Sarrazin 2016 [19]